Active Ingredient(s): Lasmiditan Succinate
FDA Approved: * October 11, 2019
Pharm Company: * ELI LILLY AND CO
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Reyvow Overview

Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.[2] It is not useful for prevention.[2] It is taken by mouth.[2] Common side effects include sleepiness, dizziness, tiredness, and numbness.[3][4] Lasmiditan was approved in the United States in October 2019 ...

Read more Reyvow Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Reyvow Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lasmiditan Succinate
  • Tablet: 100mg, 200mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Reyvow: (3 results)

Sorted by National Drug Code
  • 0002-4312 Reyvow 50 mg Oral Tablet by Eli Lilly and Company
  • 0002-4491 Reyvow 100 mg Oral Tablet by Eli Lilly and Company
  • 0002-4736 Reyvow 200 mg Oral Tablet by Eli Lilly and Company

Other drugs which contain Lasmiditan Succinate or a similar ingredient: (1 result)